Philip Morris International has doubled its market cap since January, adding $134 bn in value. The jump owes to stronger forecasts for its nicotine pouch Zyn and heated‑tobacco IQOS. Analysts now project an extra $7 bn in earnings for 2026‑2032, yet most of the lift comes from cash flows beyond six years.

British American Tobacco has seen a similar rise, doubling its share price and adding roughly £50 bn to long‑term value. The shift reflects FDA approvals that now allow Zyn to be marketed as safer than smoking, and tighter enforcement of imported Chinese products that has redirected volumes back to mainstream brands.

Cigarette sales fell 770 bn stick equivalents between 2010 and 2024, while alternative nicotine volumes rose nearly 1 tn. European regulators warn that smokeless products could lure new users, yet the current regulatory climate favors growth. Investors now treat smokeless nicotine as a incorporation of long‑term growth capital.

The market now prizes future‑proof nicotine streams, treating legacy brands as if they were tech firms. The valuation shift signals that investors expect the industry’s decline to be offset by an expanding low‑risk product line. The next wave of policy changes could reverse this trend, but current data supports sustained premium pricing.